Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.
The deal with an undisclosed "major pharmaceutical company" is focused on the evaluation of Marina's proprietary amphoteric liposomal formulations for pulmonary delivery.
According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.